Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Label Extension Application Accepted For FDA Review; Demonstrates Superiority Over Placebo For All Secondary Outcomes; Fewer Serious Adverse Events Reported In Semaglutide Group, Though More Discontinuations Than Placebo
Posted In: NVO